- Home
- SHPH vs PHIO Comparison
SHPH vs PHIO Comparison
Compare SHPH & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- PHIO
- Stock Information
- Founded
- SHPH 2012
- PHIO 2011
- Country
- SHPH United States
- PHIO United States
- Employees
- SHPH N/A
- PHIO N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- SHPH Health Care
- PHIO Health Care
- Exchange
- SHPH Nasdaq
- PHIO Nasdaq
- Market Cap
- SHPH 3.2M
- PHIO 3.4M
- IPO Year
- SHPH 2022
- PHIO N/A
- Fundamental
- Price
- SHPH $0.84
- PHIO $2.77
- Analyst Decision
- SHPH
- PHIO Strong Buy
- Analyst Count
- SHPH 0
- PHIO 1
- Target Price
- SHPH N/A
- PHIO $36.00
- AVG Volume (30 Days)
- SHPH 115.9K
- PHIO 18.5M
- Earning Date
- SHPH 11-13-2024
- PHIO 11-14-2024
- Dividend Yield
- SHPH N/A
- PHIO N/A
- EPS Growth
- SHPH N/A
- PHIO N/A
- EPS
- SHPH N/A
- PHIO N/A
- Revenue
- SHPH N/A
- PHIO N/A
- Revenue This Year
- SHPH N/A
- PHIO N/A
- Revenue Next Year
- SHPH N/A
- PHIO N/A
- P/E Ratio
- SHPH N/A
- PHIO N/A
- Revenue Growth
- SHPH N/A
- PHIO N/A
- 52 Week Low
- SHPH $0.58
- PHIO $1.53
- 52 Week High
- SHPH $4.94
- PHIO $10.35
- Technical
- Relative Strength Index (RSI)
- SHPH 49.54
- PHIO 50.99
- Support Level
- SHPH $0.83
- PHIO $2.41
- Resistance Level
- SHPH $0.92
- PHIO $4.53
- Average True Range (ATR)
- SHPH 0.08
- PHIO 0.83
- MACD
- SHPH 0.01
- PHIO 0.12
- Stochastic Oscillator
- SHPH 51.97
- PHIO 14.18
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.